Dasaldhan Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 07-11-2024
- Paid Up Capital ₹ 0.10 M
as on 07-11-2024
- Company Age 4 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.00 Cr
as on 07-11-2024
- Revenue %
(FY 2023)
- Profit 3.91%
(FY 2023)
- Ebitda -24.36%
(FY 2023)
- Net Worth -75.69%
(FY 2023)
- Total Assets 45.56%
(FY 2023)
About Dasaldhan Pharmachem
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹8.00 Cr.
Darshna Mehta, Munir Mehta, and Devansh Mehta serve as directors at the Company.
- CIN/LLPIN
U24100GJ2020PTC118108
- Company No.
118108
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Nov 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Dasaldhan Pharmachem?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Darshna Mehta  | Director | 09-Nov-2020 | Current |
| Munir Mehta | Director | 09-Nov-2020 | Current |
| Devansh Mehta | Director | 26-Apr-2022 | Current |
Financial Performance and Corporate Structure Insights of Dasaldhan Pharmachem.
Dasaldhan Pharmachem Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 3.91% increase in profit. The company's net worth observed a substantial decline by a decrease of 75.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dasaldhan Pharmachem?
Unlock access to Dasaldhan Pharmachem's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Dasaldhan Chemicals Private LimitedActive 33 years 9 monthsDarshna Mehta, Munir Mehta and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Standard Chartered Bank Creation Date: 17 Jul 2024 | ₹8.00 Cr | Open |
How Many Employees Work at Dasaldhan Pharmachem?
Dasaldhan Pharmachem has a workforce of 0 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dasaldhan Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dasaldhan Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
